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INTRODUCTION 
Cancer is a neoplastic disease condition in which the ultima te 
goal of patient and phys ician a l ike is a cure by chemotherapeutic agents, 
surgery, ionizing radiation, or other means . Most of the cancer 
chemotherapeutic agents in use today which have a degree of efficacy in 
controlling neoplastic conditions also cause a marked depression of other 
active proliferating tissues of the patient, the bone marrow, lymphoid 
tissue and intestinal mucosa. The use of these toxic chemotherapeutic 
agents causes a decrease in t he body's defense mechanisms by their 
action upon the bone marrow and other hematopoietic tis sues . They may 
also cause significant alterations in the body fluid and electrolyte 
balance by action upon the intestinal mucosa . Both of these conditions, 
if allowed to progress, can lead to death of the patient. The basic 
problem in the use of the current cancer chemotherapeutic agents is to 
achieve with a given drug adequate anti - tumor activity with the minimum 
of toxic side effects. 
The depression of the bone marrow by t hese cancer chemotherapeutic 
agents causes a condition called 11aplastic anemia" . Although "apla s tic 
anemia11 is a t erm that presently enjoys common usage, the condition 
produced is actua lly a n atrophy of the bone marrow . Aplasia indicates 
that the cells in the marrow are primordial in nature and small, but 
atrophy denotes tha t the cel lular cons tituents have decreased in size 
and/or number after ach i.evin g the normal morphology . 
Agents that cause an a trophic bone marrow in animals and man have 
been called "bone marrow poisons " . The fact that most useful cancer 
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chemotherapeutic agents have marrow poisoning properties has required 
extensive test or assay systems to evaluate the marrow poisoning 
potentials in addition to the anti-tumor potentials of the various 
compounds. 
For obvious reasons , humans have no t been used as the initial 
screening system for the anti - tumor potentials and toxic potentials of 
various experimental compounds. Laboratory animals have been used in 
rather elaborate screen ing systems and assay techniques developed for the 
detect ion of potential an t i-cancer agen t s . The mouse has been an idea l 
animal for t his evaluation because neoplastic conditions can be induced 
in them and the response to the potential anti-cancer compounds can 
be eva l uated. Concurrently this same assay system is used for the de -
tect i on of the gross t oxi cities of the c ompounds. 
Currently much attention is being directed to relating the anti -
tumor activities of compounds to details of their molecular structure, 
to fac il i t ate the deve l opment of more eff i cient anti - tumor agents. In 
contrast l i ttle emphasis is being given t o relating t he mar row poison -
ing activities of these same agents to details of their molecular 
structure . Conceivably, exploitation of this latter approach could 
facilitate the detection and subsequent e l imination of the undes irable 
toxic s t ructural groups associated with marrow poisoning pr operties of 
the compounds with retention of their anti - tumor capabi l ities . 
Utilization of this approach will require the development of an assay 
system designed specifically to quantitate the bone marrow depre ssion 
induced by chemical compounds. 
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Little work has been done in the common laboratory animals to 
establish quantitatively the effects upon t he bone marrow of the 
various structural moieties of anti-cancer agents . In contrast, t he 
calf has been used extensively to quantitate the effects of structural 
analogs of several marrow poisons upon the bone marrow . 
The calf has been shown t o be very sensitive and quantitative in 
its response to the bone marrow poisons, trichloroethy lene-extracted 
soybean oil meal (TCESOM) and S-(dichlorovinyl)-L- cysteine (DCVC) . The 
calf is also sensitive to ionizing radiation and its response pattern 
indicates that the calf is on the order of twice as sensitive to 
radiation as other species t ested. The calf's quantitative r esponse to 
several bone marrow poisons and its marked sensi tivity t o the effects of 
ionizing radiation indicate that the calf might be a very sensitive system 
for the quantitative assay of the marrow poisoning potential of anti -
cancer compounds. 
It is proposed in this investigation to eva luate the ability of 
the calf to sense and respond quantitatively to the bone marrow poison-
ing properties of several cancer chemotherapeutic agents in us e today. 
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LITERATURE REVIEW 
Assay of Bone Marrow Poisons 
Bone mar r ow t oxicity assays are init iated by administering t he 
po t ential bone marrow poison t o an animal by any of a variety of 
routes , i . e . , intravenous, intraperitoneal, intramuscular, or oral (51). 
The assays are completed by eva lua t ing t he effec t s of the c ompound for 
its marrow poisoning properties ei t her directly by examining the bone 
marrow fo r changes in the normal morpho l og i cal picture, or indirectly 
by examining the changes in the cellular constituents of the peripheral 
blood which reflect the morphological changes in the bone marrow (41, 42) . 
Administra t ion of compounds 
Potential bone marrow poisons have been administered to anima ls by 
a ll l ogical routes (7) . The route of administrat ion with the s lowes t 
absorption, i . e . , the oral route, in most cases, has caused an increased 
t oxi c effect because of the larger dosages which a r e required to r each 
the desired drug l evel in t he fluids bathing t he tissues. The prolonged 
dura tion of blood l evels of the compound due t o t he decreased rate of 
absorption also leads to an increased toxic effect of t he compound ( 24 , 16) . 
The intravenous route of administration a llows a more r apid a ttain-
men t of desired drug l eve ls in t he f luids bathing the tissues wi th l ess 
compound per unit of body weigh t. The lesser amoun t of compound in-
jected plus the speed a t wh i ch compounds can be e limina t ed f r om t he body 
after ge tting into the blood can aid in decreasing the toxicity of t he 
administered compound (15, 16). 
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The intraperitoneal route has absorption and elimi nation rates 
comparable to the intravenous route and can be used unless the 
compound is an irri t ant and is capable of producing an aseptic 
peritonitis (16) . 
Theoretically, all r outes can be used on any anima l, but generally 
the choice o f c onvenien t routes is dependent upon the experimen tal 
animal emp loyed . The oral route can be used in all animals if the 
compound can be placed i n capsules or in the food (51). The intra -
peritoneal rou t e, on t he other hand, is the method of choice for in-
j ection in t o the smal l rodents because of the inaccessibility of blood 
vesse l s for intravenous inj ec tion. The monkey and dog lend themselves 
r ead ily to intravenous injections (5 1) . 
Single dose or mu ltiple dose regimens of admini s tra tion of marr ow 
poisons can both l ead t o the production of t oxic conditions as in -
dicated by the bone marrow response (14, 21 , 22). Ferguson, e t a l . , (14) 
have shown that t he sequence of occurring events in both types of dosage 
prog rams , t he timing of the appearance of the var i ous r esponses of the 
marrow due to the effects of the bone marrow poison, may be different . 
Experimental animals 
The common labora t ory animals ; rats , mice, dogs and monkeys have 
been used as assay animal s for bone marrow poisons (8, 14, 31 , 38, 41, 42) . 
The choice of the var i ous animals has been shown to depend upon several 
criteria (51). 
The first criterium is sensitivity of the animal s t o t he compound. 
Althou gh a ll of the corranon l aboratory animals appear t o be sensi t ive to 
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most marr ow poisons, the dog has been found to be the most 
sens i tive (14, 38, 41, 42, 50). 
The mouse has been used extensively for the simultaneous assay 
of bone marrow toxicities and anti-tumor potentials of experimental 
compounds (51) . Neoplastic conditions can be induced in mice and the 
r esponse of the neoplasm to the test compounds can be determined (21, 
22, 24). The hematopoietic tissues of t he mouse are also quite 
sens itive to marrow poisons (51) . This sensitivity coupled with the 
size, availability and genetic uniformity of the l aboratory mouse has 
resulted in its wide acceptance as an assay system for marrow poison 
evalua tions . 
The size of the animal is an important cr i t erium which must be 
taken into consideration . The allowabl e frequency of sampling of blood , 
bone marrow or tissues is dependent upon the size of the animal. 
Large animals can provide samples at frequ~nt interval s and enable the 
investigator to determine the progressive response of the animal(s) to 
the effects of the administered compound (3 8, 41, 42) . The smaller 
animals, on the other hand, are suitable if sampling is done only a t 
necropsy (8) . 
Evaluation of toxicity 
The evaluation of the morphological changes of the bone marrow 
in response to marrow poisons is accomplished by bone marr ow aspirations 
either in the live animal or at necropsy. (49) . Marrow smears are pre -
pared and studied to determine if a change has occurred in the normal 
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ratio be t ween t he myeloid cells and the erythroid cel l s at 2 : 1 to 
4 :1 . The change in the number of megakaryocytes present can also be 
noted at t he same time . 
Deviations from the normal morphologica l characteristics detected 
in the bone mar r ow in response to marrow poisons are an acellularity 
due to a decrease in the myeloid series and megakaryocytes . This may 
be fol l owed by a decrease in t he erythroid series depending upon the 
l eng th of the assay per iod and the toxici ty of the compound (21, 48, 50). 
The peripheral blood commonly ref l ects t he atrophy of the bone 
marrow . This reflection occurs because the cells in t he marrow have 
been shown to be precursors of the cel l s in the peripheral blood (49). 
The thrombocyte decrease is the first response of poisoned mar r ow 
detectable in the peripheral blood (28 , 41, 42), and ref l ects a 
megakaryocyte decrease . A leukopenia due t o a decrease in t he myeloid 
series and an impair ment of lymphoid ti ssue, and an anemia corres pond -
ing t o t he erythroid series decrease are a l so de tectable . 
Bone marrow poisons also affect other tissues characteri zed by r apid 
pro liferat i on causing a decr ease in gr owth and function . These tissues 
are characterized by the s tratified squamous epithelium of t he skin and 
the gastrointestina l mucosa (20 , 28, 41, 42) . 
Death and the time of dea th have been used as qualitative and 
quantitative criteria in marrow toxicity assays in addition to the de -
t ectabl e marrow responses (14 , 41, 42) . 
The a trophy of the bone marrow and other hematopoietic t issues due 
to the marrow poisons can l ead to a decrease in the activity of the 
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animal's defense mechanisms. The effects of the marrow poisons upon 
the intestinal mucosa can alter the body fluid and electrolyte 
balance . Both of these conditions if not corrected can lead to the 
death of the animal. Death as a result of these secondary sequela 
due to the effects of bone marrow poisons has given the most qualitative 
and quantitative responses (14, 41, 42) . 
Early death has been shown to occur if very large amounts of bone 
marrow poisons have been given, but the mechanism(s) of action in this 
early death has not been established (7). Calabresi and Welch (7 ) have 
postulated that the bone marrow poisons in some manner affect and alter 
metabolic activities concerned with the homeostatic process . They 
further state that the alterations in the homeostatic processes, can 
l ead to death. 
Calf Assay Systems 
Young calves have been utilized as experimental animals in a wide 
var ie t y of assay techniques . They have been used as the assay animals 
in nutrition experiments (3, 12, 19, 35) and in toxicological ex-
periments with insecticides (29). 
The young calf was found to be the ideal animal for the detection 
of toxic trichloroethylene-ex tracted soybean oil meal (TCESOM), the 
toxic principle of which turned out to be a potent bone marrow 
poison (33, 34, 36). Assay t echniques using the calf were deve loped to 
determine the amount of toxic principle ~n various preparations of the 
toxic meal (36), and also to determine the amount of toxic principle 
9 
found in various fractions of the t oxic mea l s (34 , 46). These find -
ings led to its being used as an assay system for other bone marrow 
poisons ; S- (dichlorovinyl) -L-cysteine (DCVC) (25, 26, 27, 43) and 
bracken fern , Pteridium acguilinum (13). 
TCESOM and DCVC assays 
The hematopoietic system of the young calf has been shown t o be 
very sensitive to the effec ts of the "aplas tic anemia 11 producing 
substance(s) in toxic TCE SOM (30, 33, 34, 36) and to DCVC (25, 26, 27, 
43) . Laboratory animals, mice, rats, guinea pigs, rabbits and dogs 
in contrast did not show the typica l response of an ap l astic anemia or 
a blood dyscrasia with TCESOM (37) . Likewise, the r at failed to show the 
typica l ap l astic anemia response with DCVC (11) . 
The calf responds to the bone marrow poisons TCESOM and DCVC, like 
corranon laboratory animals respond to other bone marrow poisons with an 
i mmediate thrombocy topenia and a l eukopenia with a relative l ymphocytos is 
(26, 27, 43) . The thrombocytopenia seen in calves in r esponse t o DCVC 
and TCESOM is much more severe than the thrombocytopenic response of 
l aboratory animals due to other bone marrow poisons . Prominent 
hemorrhagic signs were observed consistently along with the thrombo -
cytopenia in calves (3 0, 46) . Following the thrombocytopenia and 
l eukopenia with a relative lymphocytos is, a severe leukopenia and an 
anemia ensued if the assay period was prolonged . 
Investiga tions have also shown that the occurrence of death and the 
time of death of the ca lf in response to the administration of TCESOM 
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and DCVC were also excellent criteria for quantitative assays of 
discrete dosage levels of both substances (25, 26, 27, 42) . 
The young calf has been found to respond quantitatively to large 
single dose or smaller daily dose regimens of TCESOM (25, 26) and 
DCVC (27, 42) . The response of the calf has been shown t o be very 
predictable for both programs . 
Schultze,~ al . , (43) have conducted thorough comparative 
evaluations in calves of the changes observed in the cellular con -
stituents of the peripheral blood and the changes observed in smears 
from bone marrow aspirations in response to bone marrow poisons , TCESOM 
and DCVC . They found that the changes in the peripheral blood reflected 
accurately the morphological changes observed in the bone marrow smears . 
Gamma radiation response 
The young calf has been shown to be sensitive to gamma radiation (39). 
The sequence of events observed in the peripheral blood in response to 
t he gamma radiation was a very severe l eukopenia within t wo days with a 
thrombycytopenia occurring later. This response in the calf was similar 
to that observed in other species (9, 23) . 
The reported sensitivity of the calf to gamma radiation and the 
observed radiomimetic response of the calf to TCESOM and DCVC led 
Schultze and co-workers (44) to determine in detail the effects of gamma 
radiation on the young calf . They were able to ascertain that not only 
was the calf sensitive to the effects of. gamma radiation quantitatively, 
within prescribed limits, but also that the young calf was on the order 
of a factor of two times more sensitive than other ma!Tlllalian species . 
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Laboratory investiga tions have demonstrated that the calf was 
extreme ly sensitive to two bone marrow poi sons, and that the calf 
appeared to be appre cia bly more sen s itive than other animals to the 
effects of gamma radiation . The reported increased sensitivi t y of the 
calf suggests tha t this animal might be the animal of choice for a very 
sensitive assay system for bone mar r ow poisons. 
Cancer Chemot herapeutic Agents 
Modes of action 
Certain effective cancer chemotherapeutic agen t s which are also 
bone marrow poisons have been shown t o act in metabolic pathways 
invo lving nucle ic acids (5, 20). Investiga t or s have demons trated that 
these c ompound s block nucle ic acid synthesis, interfere with t he 
transcrip tion of the gen e tic informa t ion from desoxyr ibonucleic acids (DNA) 
t o ribonucleic acids (RNA) and cause an abnormal trans l at ion of th e 
message into peptide chains and proteins. These interferences with nucle ic 
acid metabolism have been shown to b l ock norma l mi totic activity (20) . 
While the mechanisms of action of mos t anti-neop l a stic a gent s are those 
mentioned above, n ew chemotherapeu t ic agent s have been empl oyed whose 
mechanisms of action have not been established or are only partia l l y 
known . These new anti -cancer compounds have a l so been shown to be bone 
marrow po ison s (5, 7, 20) . 
Neoplasms or tumors have been demonstra t ed as condi tions in which 
the active prol iferation of the affec t ed cells is increased or at leas t 
a ltered in some manner (2) . Abraham (1) has postu l ated tha t 
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chemotherapeutic agents which appear to interfere with t hese ac t ive 
proliferating tumor cells might adversely affect tissues in the body 
which normally show active proliferation. Brockman (5) has cited several 
ins t ances in which i t has been established that these compounds affect 
not only the neoplasms but also the bone marrow, t he intes t i nal mucosa 
and the epithelium of the skin. 
Classificat ion 
Many different t ypes of compounds have been used as anti -ca nc er 
agents (7). With few exceptions, these agents can be placed into two 
ma.in groups : alkylating agents and antimetabolite compounds . 
Alkylating agents which have been in common use as chemotherapeutic 
agents in the treatment of cancer for many years have mechanisms of 
ac tion which have not been clearly elucidated (2 8) . Karnofsky and 
Clarkson (2 0) have cited several suggested mechanisms of action for 
alkylating agents . They ind ica ted that the major site of action is 
probably the alkylation of the 7-nitrogen of guanine . It was suggested 
t hat akylation at t his point may cause an easier sciss i on of the sugar 
bond possib l y l eading to a break in t he DNA chain . 
The antimetabolites on the other hand are placed in two categories; 
pu r ine a nd pyrimidine base analogs and dietary essen tial analogs . 
The purine and pyrimidine analogs, which may be typified by 6-
mercaptopurine and 5 - f luoro uracil (5-FU), have been shown to act as 
inhibitors of the corresponding purine or pyrimidine bases in nucleic 
acid metabolism. This inhibition can block DNA or RNA synthesis and 
interfere with protein synthesis (5, 8) . The dietary essential a na l ogs , 
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of which the anti-folic acid compounds are typical, have been shown 
to interfere with those reactions in which the nutrient is required as 
a co-factor (5, 18) . 
Mechlorethamine·HCl and uracil mustard 
Mechlorethamine ·HCl (methyl-bis(~-chloroethyl)amine) and uracil 
mustard (5 - bis(2-chloroethyl)-amino uracil) are alkylating agents which 
have been used as cancer chemotherapeutic agents (28) . The structures 
of these two compounds are as fo llows : 
Mechlorethamine ·HCl Uracil mustard 
These two compounds are polyfunctional alkylating agents, i . e . , they 
have more than one active site . Both of these agents have been shown 
to cause cross-linking between two different guanines on the same DNA 
chain or on two separate DNA chains (20). Shanbrom, et ~· , (47) indicate 
that uracil mustard because of its carrier structure, uracil, may also 
interfere with tumor metabolism by acting as a pyrimidine analog . 
Subacute and chronic toxicity studies with mechlorethamine·HCl and 
uracil mustard have indicated that both cause similar qualitative r e -
sponses in assay animals (24, 41, 42) . The two compounds cause an 
initial hematopoietic tissue depression followed by gastro-intestina l 
upsets and death . The first sign of the hematopoietic t issue depression 
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was a thrombocytopenia . This was followed by a granulocytic and 
lymphocytic l eukopenia with an ensuing depression of the erythrocyte 
counts and hemoglobin value . 
Rats injected intraperitoneally with uracil mustard at dosage 
l evels of 1 mg . /kg . /day developed toxicity symptoms (24) . Quantitative 
and qualitative studies in monkeys and dogs treated with mechlore-
thamine ·HCl at six dosage levels between 0 . 021 and 0 . 672 mg . /kg . daily 
have indicated that both the monkey and the dog respond in a similar 
qualitative manner at a ll of t he dosage l evels used. The dog as in-
dicated by the response of the thrombocytes and the gastr o- intestinal 
mucosa appeared to be more sensitive to the effects of this nitrogen 
mustard than the monkey . Death occurred earlier in monkeys even 
t hough they did not show the early sign s of sensitivity exhibited by 
the dog to this compound (41, 42) . 
5-Fluoro uracil (5-FU) 
5- Fluoro uracil (5 - FU) is a pyrimidine analog, very similar in 
structure to thymine . The structures of these two compounds are shown 
below : 
5- Fluoro uracil Thymine 
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Most of th e evidence has indicated tha t the mechanism of act i on 
of 5- FU is to inhibit the enzymes involved in nucleoside and 
nucleo tide synthesis, specifically t hose of pyrimidine nucleosides and 
nucleotides (10) . The most profound inhibi tory effect of 5- FU has 
appeared to be in the synthesis of DNA thymidine . The 5 ' deoxyriboside 
of 5- FU has been shown to cause an irreversible inhibition of the enzyme 
thymidylate synthetase (8). Severa l other effects of 5- FU have been 
demonstrated due to its incorpora tion into ribonucleotides and 
polyribonucleotides, among which have been demonstrated are abnormal -
ities in protein synthesis (5) . 
Subacute and chr onic toxicity studies with 5- FU in mice, rats, dogs, 
and monkeys (49) and in humans under clinical study (17, 48) have in -
dica t ed t hat the primary sign is a hematopoietic tissue depress ion . 
This is followed by intestinal mucosa damage and death. 
Mice tr eated with 5- FU at a dosage level of 40 mg . /kg . /day for 
6 days have shown severe depressions of t hrombocytes , neutrophils , 
l ymphocytes and erythrocytes (22) . With dosages of 25 mg . /kg . /day, for 
14 days only mild changes occurred in the peripheral blood (22) . 
Dogs injected intramuscularly with 5- FU at levels of 2 . 5 mg . /kg./day 
for 30 days showed toxicity signs , but monkeys required 10 times t hat 
amount to produce toxicity signs (50) . 
Humans with cancer have been given 5-FU at dosage levels of 4, 
6 or 8 mg . /kg ./day for periods of 14 t o 42 days (17, 48) . Mild toxicity 
s i gns of slight hematopoietic tissue depression were observed in patients 
treated a t the lower dosage schedules . More severe signs of increased 
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hematopoietic tissue depression and gastro- intestinal upsets were 
observed with the progressively higher dosage levels. 
Amethopterin 
Ame t hopterin is an analog of folic acid which has a molecular 
structure similar to t hat of folic acid (pteroylglutamic acid) as shown 
be l ow : 
~c-c, 
c......__ / C- CO - NH- CH-COOH 
"C= C I 
(CH2 )2 
I 
COOH 
Folic Ac id 
C[ H3 C C 
NH ~ - ~ 
I 2 N--- C C- CO-NH-CH- COOH " cH ' c= c/ I ~C, /N~ / 2 ( ) 
N ' C ~, CH2 2 
NH -! ~ C ~OH 
2 ~/ '-..N~ 
Amethopterin 
The structural differences between folic acid and amethopterin are an 
amino group attached to position 4 and a methyl group attached to 
posi t ion 10 . Amethopterin prevents t he reduction of fol i c acid by in-
hibiting dihydro- folic acid reductase (18) . Jukes (18) has presented 
evidence to indicate that this enzyme has an affinity for amethopterin 
about 100 , 000 t imes greater than folic acid . This reduction step has 
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been shown to be a necessary reaction in the methylation of 
deoxyuridine monophosphate (dUMP) to form thymidine monophosphate (TMP) . 
Comparative studies with amethopterin have been conducted with 
mice, rats and dogs (14, 31, 38) . Additional informa tion has been 
derived from clinical studies on humans (28) . These studies indicated 
t hat the initial signs of a t oxicity in response to amethopterin are 
those of hematopoietic tissue depression. These initial signs are 
fol lowed by digestive upsets and death. 
Evidence has been presented tha t the dog is more sensitive to 
amethopterin than are rodents (38). Intra -muscular injections of 
amethopterin of 1 . 0, 0 . 2 and 0 . 05 mg./kg./day e licited varying toxicity 
responses in the dog . The onset of the toxicity signs was shown to be 
dependent upon the amount of compound given . Animals receiving the 
greatest amount of compound per unit body weight showed the earliest 
signs. The time of death of these animals appeared to reflect the 
dosage levels quantitatively (14) . 
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MATERIALS AND ME THODS 
Experimental Animals 
Male Holstein calves weighing 32 to 45 kg. were purhcased from a 
single l ocal source. Upon receipt, the calves were given a preventative 
2 ml . injection of an antibiotic. 
1 
A second 2 ml . injection of the 
antibiotic was given a t a later time if necessary. 
The calves were housed, two per s tall , in clean, well ventilated 
concrete stal l s which were bedded with straw. These s t alls were 8 feet 
by 8 feet with corresponding outside sta ll s of the same type for 
access in good weather. 
The rations consisted of a commercial p owdered milk pr e paration
2 
with grain, a l falfa, a mineralized salt b l ock and fresh water availab l e 
a t a 11 times . 
After receipt, t he calves were conditioned for a period of one to 
two weeks . This condi t ioning period was essential to make sure the 
calves were healthy . Thi s period was also used to check the peripheral 
blood picture several times to determine if it fel l within the re -
cognized normal limits described by Schalm (40). 
During the experimental procedures, the rectal temperatures and the 
weights were taken weekly . Clinical examinations were made daily on 
1 Penstrep, Merck; Procaine penicillin G, 200,000 units and the 
sulfate salt of dihydrostreptomycin, 0.25 gm . per ml. of solution . 
2Dari Dri; Milk Specialties, Inc . , Dundee , Illinois. 
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each calf to detect signs which might have been due to the effects 
of the test compounds. 
The hair on the necks of the calves was kept closely clipped over 
the jugular vein to allow adequate disinfection of the area . Blood 
1 
samples were collected from the jugula r vein with sterile, siliconized 
needles and syringes . A drop of blood was placed immediately on a 
paraffin block for thrombocyte count dilutions. Five milliliters of 
blood were then placed in a rubber stoppered glass container which was 
siliconized and contained 5 mg . of the dipotassium salt of ethylenediamine-
t et r aacetic acid as the anticoagulant . Blood samples were obtained at 
least twice a week from the test animals and more often as changes 
occurred in the cellular constituents of the peripheral blood. The 
control calf was bled once a week . 
Test compounds were administe red by injection into the jugular 
vein. Daily doses were given on the basis of a prescribed amount of 
compound per unit of body weight . The amount of compound injected daily 
was adjusted each week following the weighing to allow for the change 
in weight . 
Test Compounds 
The anti-cancer compounds used in this investigation were obtained 
from a local retail source . 
1
siliclad; Clay -Adams, Inc ., New York . 
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Mechlorethamine·HCl (Mu stargen-Merck) 
The mechlorethamine·HCl was furnished in sterile 10 mg . vials . 
This compound was reconstituted daily with 20 ml . of sterile water to 
make a final concentration of 500/µg. per ml . The excess solution was 
discarded. 
Uracil mustard (Upjohn) 
The uracil mustard was supplied in one mg . capsules. The contents 
of the capsules were emptied into sterile volumetric flasks of a 
sufficient size. One ml . of dimethylacetamide was added for each mg . 
of compound as suggested by Schumacher and O' Connell (45) to increase 
the solubility of the uracil mustard. Sterile water was added to adjust 
the final concentration to one mg. per 5 ml . An additional solution 
consisting of one ml . of dimethylacetamide in 5 ml . of sterile water was 
pre pared . Both solutions were made fresh daily and the excesses discarded. 
5-Fluoro uracil (Fluorourac il-Roche) 
5-Fluoro uracil was furnished in 10 ml. vials in an injectable 
form. The concentration was 50 mg . per ml . The solutions after opening 
were stored at room temperature until used, or until a white precipitate 
formed in the bottom of the vial . 
Amethopterin (Methotrexate sodium-Leder l e ) 
The amethopterin was suppl ied in 50 mg . sterile vials. The compound 
was reconstituted with 20 ml. of sterile water to make a final concen -
tration of 2.5 mg . per ml. The solutions were stored at room tempera tures 
unti l used . 
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Peripheral Blood Evaluations 
The parameters measured in the peripheral blood were total 
thrombocy te counts, total erythrocyte counts, total leukocyte counts , 
diffe r en t ial l eukocyt e counts, hematocrit and hemoglobin determina t ions . 
These techniques have been described by Wintrobe (49) or Scha l m (40) . 
Reagents 
1. Rees-Ecker dilution fluid (49) 
Sodium citrate 3.8 Gms . 
Brilliant cresyl blue 0.05 mg . 
Formaldehyde, 40%, neutral 0 . 2 ml . 
A sufficient quantity of water to make a t otal volume of 100 ml . 
2 . 5% Acetic Acid 
Glacial Acetic Acid 5 . 0 ml . 
A sufficient quantity of water to make a total volume of 100 ml . 
3 . Drabkin ' s Solution for hemoglobin det ermination (48) 
4 . 
5 . 
Sodium bicarbonate C.P. 1 . 0 Gm . 
Potassium cyanide C.P . 52 mg . 
Potassium fer r icyanide C. P. 198 mg . 
A sufficien t quantity of water to make a tota l vo l ume of 1000 ml . 
This solution was stored in a brown bott l e . 
1 
Wright ' s Stain 
1 
Phosphate buffer solution 
Giordano pH 6 . 4 
1 
Prepared by Hartman-Leddon Company, Philadel phia, Pa . and obtained 
from A. H. Thomas Co . , Philade lphia, Pa . 
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Thrombocyte counts 
The Rees - Ecker method of thrombocyte enumeration described by 
Wintrobe (49) was the procedur e fo llowed . The dilutions were made 
directly at the time of obtaining the blood sampl e . Five groups of 
16 s quares in the hemocytometer were counted and the t o ta l number of 
thrombocytes was multiplied by 5,000 to calcu l ate the number of 
thrombocytes per cu . mm. 
Erythrocyte counts 
The erythrocytes were enumerated using the method described by 
Schalm (40) . The Rees-Ecke r diluting fluid was used instead of the 
described diluting fluid. 
Tota l l eukocyte counts 
The leukocytes were counted by the method described by Schalm (40). 
Five percent acetic acid was used as the diluting fluid and hemolyzing 
agent . 
Differential leukocyte counts 
Blood smears were made as described by Schalm (40) . The Wright ' s 
staining method was used . The stain was applied for a one- minute period . 
A similar quantity of the buffer solution was mixed with the s t ain and 
a llowed to stand on the slide fo r a five - minute period . The s l ide was 
washed with water, air dried and examined by oil immersion techn i ques . 
Hema tocrit 
The hematocrit or packed cell vo l ume (PCV) was de t ermined by the 
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micro- hematocrit method (40). 
1 
A Clay -Adams microhematocrit centrifuge 
and micro-hematocrit reader were used in this procedure . 
Hemoglobin determinations 
The cyan-methemoglobin (49) method for hemoglobin determinations 
was used in this procedure . The B & L Spectronic 202 was used to 
measure the percen t transmission. 
Necropsy Techniques 
Necropsies were performed on all experimental animals . All 
observed gross l esions were noted and recorded for subsequent eva l uations . 
1 
Clay-Adams, Inc . 
2 
Bausch and Lomb, Inc ., Rochester, N.Y . 
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EXPERIMENTAL 
The experimental plan developed for this investigation was designed 
to supply for each of the cancer chemotherapeutic compounds tested 
answers to the following questions: 
1. Can the calf sense the marrow poisoning activity of the compound? 
2. Can one or more of the responses observed in the calf to the 
compound be quantitated? 
3. Are the responses to the compound observed in the calf comparable 
to those obser ved in other species of laboratory animals for the 
same compound? 
4. Are the responses to the compound observed in the calf comparable 
to those observed in calves poisoned with TCESOM and DCVC? 
The initial goal for each compound tested was the determination of 
a level of daily compound administration that would allow the depression 
of the marrow and hematopoietic tissues to occur at a rate that would 
result in the death of the calf between 30 and 60 days . At these rates 
of marrow and hematopoietic tissue depression in the calf, the signs and 
symptoms characterizing this depression have been shown to appear in an 
orderly and progressive manner. Hematologic signs in the peripheral 
blood, a progressive thrombocytopenia, leukopenia and relative lympho-
cytosis, are followed by clinical sign s of a decrease in the rate of gain, 
general loss of condition, hemorrhage, temperature spike, diarrhea, and 
death. At the necropsy examination, the classical signs associated with 
a marrow depression are commonly observed. Petechial and ecchymotic 
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hemorrhages observed throughout the body cavities and tissues and a 
b l ood t inged fluid in the body cavities are common findings . That t he 
cal f is capab l e of manifesting this orderly qualitative response to 
marrow poisons has been t horoughly subs tantiated by extensive studies 
with TCESOM (33, 36), DCVC (44) and ionizing r adia t ion (39, 45) . 
The second of t he goals for each of the compounds was to at t empt to 
obtain an indication as t o whether any of the r esponses observed could 
be quantitated with dosage l evels . Evaluation of t he abi l ity of the calf 
t o r espond in a quantitative manner to gr aded dosages of a given compound 
invo l ves t he selection of several dosage levels t hat wi ll r eflect with 
one or mor e of the various signs associated with mar r ow depression, a 
dose- degree of r esponse-time relationship that is quantitative in nature . 
Ex t ensive s tudies with TCESOM and DCVC have established that the calf 
is capable of such a quanti t ative response to these poisons (33, 43). 
The se l ec tion of c ompounds for evaluation from the ar r ay of cancer 
chemotherapeutic compounds in use today was guided by the fol l owing 
criteria: 
1 . Compounds selected shou l d have demonstrated a degree of success in 
human t herapy . 
2 . Compounds selected have been evaluated for marrow toxicity in other 
experimental animals . 
3 . Compounds se l ected should include both the alkylating and anti -
metabo l ite types. 
4. Compounds se l ected should be suitable for intravenous injection . 
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Mechlorethamine ·HCl and uraci l mustard were selected as being 
r epresentative of the a lky l a t ing type compounds. Uracil mustard is a 
structural ana log of mechlorethamine·HCl and might have a different degree 
of ac tivity due to the substitution of the uracil moiety for the me t hy l 
group . It is also possib le t ha t t he substituted uracil might ac t as an 
antimetabolite in pyrimidine me tabo lism. 
The compounds, 5- fluoro uracil and amethopterin, are repr esenta tives 
of the antimetabol ite class of cancer chemotherapeutic agents. 5-Fluoro 
uracil is a lso a structural analog of uracil musta r d since in both cases, 
the uracil moiety is subs tituted at the 5' position . Amethopter in is an 
antimetabolite of folic acid . 
The dosage regimen selected was t hat employed by McKinney , et al . , (25) 
with DCVC, daily doses of t es t compound administered by the intravenous 
route. The selection of the initial daily dosage l evels for admin is tra -
tion of the compound s to ca l ves was based on approximations derived from 
l evels employed in human chemotherapy (7). Subsequent dosage l evels were 
increased or decreased by factors of 2 until the desired r ates of 
depression of the marr ow were a ttained . 
All of the experimen tal data, exc lusive of necropsy observations, 
have been compi l ed in graphic form for presenta tion . These data, grouped 
according to the compound t ested , appear in the appendices. SullUlla r y 
t abu l a tions ex trapolated from these raw da t a appear as t ab l es in the t ex t . 
Control Ca lf 
The calf 947 was maintained throughout the investiga t ion as a 
control for the purpose of establishing the normal varia t i on s that might 
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appea r in the hematologic and clinical parameters being measured due t o 
the ages of the calves, experimenta l manipu l ations and environmen tal 
factors . The parameters measured in this calf were t otal t hrombocyte 
counts, total e rythr ocyte counts , total l eukocy t e counts, differential 
l eukocyte counts and hematocrit and hemoglobin determinations. The 
differential l eukocyte coun t s were converted t o absolute values for 
graphic presentation . None of the er ythrocyte data obtained for the 
control and experimenta l calves has been presented in graphic form in 
the appendices because no significant variations were obser ved . 
The one to two week conditioning period al l owed each animal to serve 
as its own experimenta l control. Thi s conditioning period was used to 
establish t he normal, pre -test parameters for each calf . 
The control calf was a l so observed daily along wi th t he exper i menta l 
calves for t he appearance of t he signs and r espons es that have been 
reported as being observed in laboratory animals poisoned with the 
specific marrow poisons under investigation, as well as the signs and 
responses observed in the ca l f due t o the effects of administration of 
DCVC . 
Mechlorethamine ·HCl 
The data presented in Appendix II and summarized in Table I give the 
biological responses of the young ca l ves given gr aded dai l y doses of 
mechlorethamine ·HCl . 
The mech l orethamine ·HCl adminis t ered to ca l f 844 ( 14 . 85 µg . /kg . / day) 
and calf 942 (30 . 8 µg . /kg . /day) appeared to produce a slight hematopoietic 
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Table I. The biologica l responses of young calves t o mechlor e thamine ·HCl 
Calf No. 844 942 977 953 958 
Dosage data 
Amount /kg . /day (µ.g . ) 14.85 30. 8 59 . 4 118 .8 118. 8 
(µ. moles) 0 . 0772 0 .1599 0 . 3884 0.6178 0 . 6178 
Total Cpd . given (mg . ) 146 . 88 126.014 162 . 786 81.594 59 . 832 
Weigh t of calf - initial 128 101 115 115 90 
max . 289 157 130 115 90 
Final 289 157 130 115 90 
DAYS TO DEVELOP 
Hema t o logic s i gns 
Thrombocytopenia 
Initial decline 3 33 11 
23 never never 
Below 200 , 000/mm3 60 54 34 
never never 
150,000/mm3 never never 
34 never never 
100,000/mm3 never 
never 37 never never 
50, 000/mm never never 47 never never 
L·eukopenia 3 Be l ow 5,000/mm3 
never 22 4 5 1 
3,000/mm3 
never never 20 9 5 
2,000/mm3 
never never 20 never 5 
1, 000/mm never never 43 never never 
Lyrnphocytosis 
Above 80% 52 22 20 8 2 
85% never 22 20 never never 
90% never never 41 never never 
95% never never 41 never never 
Clinica 1 s i gns 
Temper ature spike never never 39 11 7 
Diarrhea never never 37 8 6 
Dea th 108~" 73* 47 13 12 
Necropsy 
Les i on s observed no no yes yes yes 
Typical lesions of a 
marrow hypoplasia no no no no no 
* Th is anima l was ki lled, and had a normal appearance . 
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depression . The dosage levels were apparently too low to elicit the 
desired hematologic responses and the times of death were far in excess 
of the desired 30 to 60 days. The increased dosage did appear t o 
materia lly affect the growth rate of calf 942, which can be observed 
by comparing Figur es 7 and 10 of Appendix II . 
The compound administered at the next higher level, calf 977 
(5 9 µg . /kg./day), produced an orderly and progressive hematopoietic 
tissue depression, diarrhea, temperature spike and death. The time of 
detection of a significant leukocyte depression was sooner than the 
occurrence of a significant thrombocytopenia . All of the responses 
occurred within the 30 to 60 day period indicating t hat this dosage l evel 
is within the assay range . 
The dosage leve l of 118 . 8 µg./kg./day adminis tered to calves 953 and 
958 appears to be too high to elicit the desired hematologtc effects in 
the calves . A very rapid onset of a leukopenia was observed in both 
calves, but the thrombocytopenia and relative l ymphocytosis apparently 
did not have sufficient time to develop prior to death. The animals 
were markedly affected by this l evel of the compound as evidenced 
by the l ack of growth and the ear l y appearance of the temperature spike 
and the severe diarrhea . 
The gross lesion s observed at necropsy in calves 977, 953 and 958 
consisted of moderate numbers of petechial hemorrhages on the ser osa l 
surfaces and in the heart. Severe pneumonia-like lesions were observed 
in the lungs of calf 977, and moderate lung l esions were observed in 
calf 953. There was an apparent splenic hypoplasia observed in calf 977 
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which was ind icative of a hematopoietic tissue depression . While pe t echial 
hemorrhages of the serosa l surfaces are typical findings in calves 
poisoned with TCESOM and DCVC, t hese lesions a ppear only after ex t ended 
periods of a severe t hrombocytopenia . Of these ca lves , only calf 977 
exhibited a thrombocy topenia of a degree suggesting any association of t he 
hemorrhagic appearance with the administered compound . 
The pneumonia-like l esions were t hough t to be due to an acute 
septicemia caused by an overwhelming bacterial infection, possibly due t o 
a decrease in the a nimals 1 defense mechan isms resulting from the activity 
of the compound on the hematopoietic tis sues . 
The 59 . 4 µg . /kg . /day l evel of the mechlore thamine·HCl pr oduced an 
i dea l r esponse in the peripheral blood indicating an order l y depression 
of the hematopoietic tis sues l eading t o death of the anima l . The 
responses observed in the calf at this l evel are c ompar able t o t hose 
r eported in monkeys and dogs (41, 42 ). These responses did not appear to 
be as severe as th ose observed in calves due to DCVC . 
A quantitative assay range for mechlor ethamine ·HCl was not 
established but it a ppears as if the 59 . 4 µg . l evel cou l d be appr oximately 
in the middle of the desired range . These data indicate t ha t l eve l s 
could be surveyed at higher and l ower l eve l s than t he 59 . 4 µg . l eve l to 
determine the desired range . The time of death is suggestive of a 
quantitative response to this compound but insufficient numbers of calves 
were observed to a llow a definite conclusion to be made . 
The calf appear s to be mor e sensitive to mech l orethamine ·HCl by a 
fac t or of at l eas t 2 t han t he monkey and dog . The assay range for the 
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monkey and dog is 21 t o 672 µg./kg . /day (41, 42), but a range of 15 
to 119 µg . /kg./day produced similar responses in calves . 
The response of the calf to mechlorethamine·HCl in comparison to 
the responses of the calf to DCVC are somewhat different. Hematopoietic 
tissue depression and death are the common responses, but the visible 
hemorrhages, fecal blood and t ypica l lesions of an aplastic anemia 
described by McKinney, ~ ~· , (2 5) were not obser ved in these investi -
gations. 
Uraci l Mustard 
The data presented in Appendix IV and summarized in Table II give 
the biological r esponses of young ca l ves given graded daily doses of 
uracil mustard . 
Uracil mu stard is but sparingly soluble in water . Dimethylacetamide 
ha s been used to increase the so lubility for purposes of intravenous 
inj ections in human therapy and experimental work (45) . Since the effect 
of dimethylacetamide on the hematopoietic tissues of the calf was 
unknown, d ime thy l ace t amide in sterile water was injected intravenous l y 
to calf 945 at l eve l s corresponding to amounts recommended for its use 
as a so lublizing aid for uracil mustard intravenous administration (45) . 
The amount of dimethylacetamide admin istered to calf 945 was 0 . 022 
ml . /kg . /day . Comparison of the data in Appendix II for calf 945 with the 
data presented in Appendix I for t he control calf indicates that 
dimethylacetamide did not elicit a hema t o l ogic response in calf 945 . To 
complete the eva l uation of the possible effects of the use of 
dimethylacetamide as a so l ublizing aid for uracil mustard administration, 
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Table II . The biological responses of young calves to uracil mustard 
Calf No . 946 
Dosage data 
Amount /kg . /day (µg .) 22 
(µ moles) 0 .0833 
To t al Cpd . given (mg .) 153.95 
Weight of calf - initial 100 
max . 229 
Final 229 
Hema t ologic signs 
Thrombocytopenia 
I nitial decline 3 Below 200,000/mm3 150,000/mm3 
100,000/mm3 
50,000/mm 
Leukopenia 3 
Below 5,000/rran3 
3, 000/mm3 
2,000/nnn3 
1,000/mm 
Lymphocytosis 
Above 80% 
85% 
90% 
95% 
Clinica l signs 
Temperature spike 
Diarrhea 
Dea th 
Necr opsy 
Lesions observed 
Typica l lesions of a 
marrow hypoplasia 
27 
31 
never 
never 
never 
11 
45 
62 
62 
41 
52 
90 
94 
never 
never 
104* 
no 
no 
979+ 
22 
0 . 0833 
131. 900 
95 
202 
202 
952 
44 
0.1663 
151. 06 
99 
150 
148 
DAYS TO DEVELOP 
16 
23 
61 
61 
never 
16 
26 
65 
never 
30 
65 
65 
79 
never 
never 
lOl·k 
no 
no 
27 
29 
41 
41 
never 
6 
27 
34 
63 
13 
34 
34 
57 
53 
61 
66 
yes 
no 
+Dimethylacetamide was not used as a solvent . 
956 
88 
0 . 3326 
69. 8 
72 
90 
90 
15 
18 
22 
22 
never 
2 
2 
5 
17 
22 
never 
never 
never 
12 
9 
23 
yes 
no 
*ca l f was killed . Th e anima l had a norma l appearance . 
955 
88 
0 .332 
48 . 0 
72 
72 
68 
never 
never 
never 
never 
never 
1 
4 
10 
never 
3 
3 
never 
never 
12 
12 
17 
yes 
no 
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uraci l mus t a r d was administered with and without added dimethylacetamide 
to two calves, calf 946 (uracil mustard a t 22 µg . /kg . /day with 
dimethylacetamide) and ca l f 979 (uracil mustard a t 22 µg . /kg . /day withou t 
dimethylacetamide). The data in Table II show that both calves ex -
hibited comparable progressive and orderly depressions of the cellular 
cons tituents of their peripheral bl ood . There did not appear to be any 
significant differences that could be ascribed to t he additi on of 
dime t hylace t amide or to any increase in solubility of t he uraci l mustar d . 
While the l eve l of uracil mustard (22 µg ./kg . /day) was high enough t o 
elicit a definite hematopo i etic tissue response, it was t oo low t o pro-
duce death between 30 and 60 days. 
It was decided t o use the dimethylacetamide for the higher dosage 
leve ls of uraci l mus t ard to faci lita t e dispersion of t he compound for 
intravenous injection. 
The uracil mustard administe r ed at the next higher level t o calf 952 
(44 µg . /kg . /day) elicited a very marked depression of t he hematopoie tic 
tissues as evidenced in t he peripheral b l ood up until the time of death . 
The occurr ence of a temperature spike and a diarrhea prior to death was 
also evidence that t his compound was directly affecting the animal . This 
dosage l evel a ppears to be on the low side of the assay range as de -
t ermined by the time of death. 
The next higher level of administration of uracil mustard, 88 µg . / 
kg . /day , t o calves 956 and 955, produced early death in these animals . 
In spite of the ear l y deaths, there were indications of rapid hematopoietic 
tissue depression , especially in calf 956 which exhibited an orderly a nd 
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progressive decrease in the cellular constituents of the peripheral 
blood. Both calves exhibited the clinical signs of diarrhea and 
temperature spike prior to death . 
The necropsy findings observed in calves 952, 956 and 955 were very 
similar in that there wer e many petechial hemorrhages on the serosal 
surfaces, lesions indicative of a severe pneumonia and splenic hypoplasia 
in a l l calves . Calf 952 was the only calf exhibiting an extended period 
of thrombocytopenia which would be expected to produce t he extensive 
petechiation . The splenic hypoplasias observed are indicative of 
hema t opoietic tissue depression . The appearance of the pneumonia - like 
lesions in the lungs was attributed to a secondary bacterial infection 
occur ring due to a decreased ability of the defense mechanisms to 
function . 
All of the levels of uracil mustard administered produced a marked 
depression of the hematopoietic tissues. The 44 µg . /kg . / day level 
produced desirable responses of hematopoietic tissue depression followed 
by dea t h within the desirable period of time . The experimental findings 
suggest that the calf does respond to this compound in a manner com-
parable to other laboratory animals . 
A comparison of equal molar leve ls of mechlorethamine ·HCl and uracil 
mustard injected into the calf indicates that uracil mustard appears to be 
more t oxic to calves by a factor of about 2 . It is postulated that the 
substitution of the uraci l for the methyl group could produce more 
efficient alkylation or that the uracil moiety may also act as an 
a n timetabolite affecting pyrimidine synthes is, thereby supplemen ting 
the a l kylating properties of th e compound . 
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It appears that the assay range for uracil mustard in the calf should 
fall between the 44 µg. and the 88 µg ./kg . /day dosage levels . The times 
at which death occurred in response to the 44 µg . and 88 µg . levels are 
very suggestive of quantitative responses. 
The calf does appear to be more sensitive to the effects of uracil 
mustard than the mouse or rat . Reports of other laboratory animals 
tested with uracil mustard do not appear in the l iterature . I nvestiga -
tions have shown that the mouse responds quantitatively at levels of 
1 mg . /kg . /day (24) . It has been shown that rats could tolerate dosage 
levels of 0.25 to 0 . 30 mg . /kg . /day for l ong periods of time with only 
moderate toxic manifestations (24). 
The response of the calf to uracil mustard does differ with t he 
response to DCVC (44) and TCESOM (36) in that the very severe hemorrhagic 
lesions were not observed in these calves due to the uracil mustard . 
5-Fluoro Uracil 
The data presented in Appendix V and summarized in Table III give 
the biological responses of young calves given graded doses of 5- fluoro 
uracil (5-FU). 
The initial dosage sel ected of 5-FU adminis t ered to calf 750 (3 . 96 
mg . /kg./day) produced a n almost simultaneous depression of the cellular 
constituents of the peripheral blood. The decreased rate of gain, 
temperature spike and diarrhea were evidences that this l evel of 5-FU 
was severely affecting the calf . The time of death indicated that this 
l evel of the compound was too high to e licit the orderly depression 
desired . 
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Table III. The biologica l responses of young calves to 5-fluoro uracil 
Calf No. 750 950 948 951 788 980 
Dosage data 
Amount/kg . /day (µg.) 3. 96 1. 98 1. 98 1.49 1. 49 1.49 
(µ moles) 27.9 13 . 95 13 . 95 10 . 46 10 . 46 10 .46 
To tal Cpd . given (mg . ) 2 . 764 2 . 5812 3 . 0951 2 . 263 1.2543 0 . 9679 
Weight of calf- initial 83 83 102 91 101 92 
max. 87 94 112 106 101 92 
Final 85 88 112 97 90 84 
DAYS TO DEVELOP 
Hematologic signs 
Thrombocytopenia 
I nitial decline 3 5 4 5 
30 8 6 
Below 200,000/mm3 
10 4 5 33 10 12 
150,000/mm3 
16 25 24 never 10 never 
100,000/mm3 
16 25 24 never 13 never 
50,000/mm never never never never never never 
Leukopenia 3 
Below 5,000/mm3 
12 30 20 22 6 never 
3,000/mm3 
15 31 25 33 13 never 
2,000/mm
3 
never 31 never 35 never never 
1,000/mm never never never never never never 
Lymphocytosis 
Above 80% 12 29 27 35 never never 
85% 12 30 30 never never never 
90% 13 30 30 never never never 
95% 14 31 30 never never never 
Clinical signs 
Temperature spike 15 23 22 never 15 never 
Diarrhea 16 18 23 23 15 10 
Death l~ 32 31 35 18 16 
Necropsy 
Lesions observed no yes yes no yes yes 
Typical lesions of a 
marrow hypoplas ia no no no no no no 
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The lower dosage of 5-FU administered to calves 948 and 950 
( 1 . 98 mg . /kg . /day) produced an orderly and progressive hematopoietic 
t issue depr ession wi th marked thrombocytopenia occurring prior to the 
l eukopenia . The c l inical signs observed in t hese two calves indicated 
tha t this compound was directly affecting the animals . The times of 
death of t hese t wo animals were within the desired period of time and 
were a l so indicative of a quantitative response to the dosage level . 
The l owest dosage level of 5- FU (1 . 49 mg . /kg . /day) was administered 
to cal ves 951 , 788 and 980 . Although there were hematologica l f indings 
which suggested a response to the compound, there were no consis t ent 
signs observed except t he decreased growth rate . 
The times of occurr ence of death in al l animal s injected with 5- FU 
were very i nconsistent . The i nconsistent hemato l ogica l and clinical 
signs exhibited in a l l calves were suggestive of a lack of quant i tat i ve 
response i n calves t o this compound . 
The necropsy f i ndings observed in the calves t rea t ed with 5-FU wer e 
very inconsistent . The most consistent finding was that of dehydrated 
and emaci a t ed cadavers . Ca l f 948 exhib i ted the most extensive lesions 
which consisted of petechial and ecchymotic hemorrhages of the serosal 
surfaces , white spotted kidneys , swollen liver , pneumonia and splenic 
hypop l asia . The significance of the wide array of lesions was not 
understood, bu t was attributed to a chronic condition . Calves 950, 788 
and 980 had pa t ches of pneumonia -like l esions of the lungs and calf 980 
also had white spotted kidneys. 
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The appearances of the emaciated and dehydrated cadavers of all of 
the 5 -FU treated calves were high l y indicative of a direct effect of 
5- FU upon the calves. These findings are suggestive of a very marked 
interference with the homeostatic mechanisms . 
The responses of the calf to 5-FU of an emaciation, diarrhea, 
retarded growth rate and hematopoietic tissue depression are very similar 
t o the responses repor t ed for mice, dogs and monkeys (51). The 
hematologic responses produced in the calf due to 5- FU a r e not as orderly 
and progressive as have been shown in the calf in response to TCESOM (36) 
and DCVC (44) . 
The responses of t he calf t o the graded l evels of 5-FU administered 
indicate that this animal might not be capable of quantitating t oxic 
l eve l s of thi s compound . The calf does appear to be somewhat more 
sensitive to the effects of 5-FU than the dog and much more sensitive 
than other animals . Slight t oxicity responses have been elicited in the 
dog in 30 days at l eve ls of 2 . 5 mg./kg . /day (51), but in the calf, dosage 
levels from 1 . 49 mg . to 3 . 96 mg . /kg . /day caused death within 35 days . 
The comparison of dosage levels on a mole basis indicated that the 
5- FU is no t as toxic t o the calf as uracil mustard and mechlorethamine · 
HCl . 
Amethopterin 
The data presented in Appendix VI and summarized in Table IV give 
t he biological responses of calves to graded daily doses of amethopterin . 
Amethopterin at a dosage level of 1.109 mg . /kg . /day (calves 784 and 
792) was the highest level administered and the only dosage level that 
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Table IV . The bio log i ca l responses of young ca l ves t o amethopterin 
Calf No . 842 943 978 784 792 
Dosage data 
Ainount/kg . /day (µg .) 0 . 0693 0 . 143 0 . 277 1.109 1 . 109 
(µ. moles) 0 . 1528 0 . 3153 0 . 6114 2 . 4453 2 . 4453 
Total Cpd. given (mg .) 874 . 9 572 . 62 1 ,6668 366 . 88 335 . 98 
Weight of calf - initia l 110 91 97 91 94 
max. 286 172 225 91 94 
Final 286 172 225 85 85 
DAYS TO DEVELOP 
Hema t ologic signs 
Thrombocytopenia 
I nitial decline 
3 5 never never never 
never 
Below 200 ,000/mm
3 
18 never never never never 
150,000/mm
3 
never never never never never 
100 ,000/mm3 never never never never never 
50,000/mm never never never never never 
Leukopenia 
3 Below 5, 000/rran
3 
never n ever never 3 never 
3, 000/mm
3 
never never never 6 never 
2 ,000/mm3 never never never never neve r 
1,000/mm never never never never never 
Lymphocytosis 
Above 80% never never 72 never 3 
85% never never never neve r 3 
90% never never never never 3 
95% never never never never 7 
Clinical signs 
Tempera t ure spi ke never never never never 6 
Diarrhea never never never 2 2 
Dea t h 106-J< 78-J< 87* 7 8 
Necropsy 
Lesions observed no no no no no 
Typ i cal lesions of a 
marrow hypoplasia no no no no no 
-1< 
Calf was killed . The animal had a norma l appearance . 
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indicated some hema.topoietic tissue depression . There were clear 
clinical indication s of an affect due to this level of compound con-
s i sting of severe weight l osses, very early diarrheas and the r apid 
occurrences of death . The necropsy findings of these two calves were 
normal . 
The lower levels of amethopterin administered to calves 842 , 943 and 
978, did not produce any significant hematologic or c linical r esponses . 
Typica l l esions of marrow hypoplasias have been produced i n 
monkeys , rats and dogs (14) . These lesions consisted of hematopoietic 
depression and hemorrhagic syndromes. None of t hese lesions wer e 
observed in ca l ves i n response t o amethopterin . 
High l evels of amethop t erin , 1 . 109 mg . /kg . /day, do cause death in 
the calf in a very short period of time, but none of the other r esponses 
observed in l aboratory anima l s were observed in the experimental calves . 
No quantitative responses due to the effects of ame t hopterin at t he 
l evels administered were observed in the calves . I t is postulated that 
a bacteri a l syn t hesis of fo l ic acid in the developing r umen was the 
probab l e cause of a l ack of response of the calf to amethopterin . 
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DISCUSSION 
The classica l response, almost textbook in nature, of the 
hematopoietic system of the young calf to TCESOM, DCVC, bracken fern 
and ionizing radiation has repeatedly suggested itself to those familiar 
with the calf's capabilities in this respect, that the calf might be the 
animal of choice for the qualitative and quantitative assay of bone 
marrow poisons. The need for a better assay system is readily apparent 
when considerations are made to the omnipresence of marrow poisoning 
properties of many of the cancer chemotherapeutic agents in use today . 
Experimental findings did show that the cancer chemotherapeutic 
agents, mechlorethamine ·HCl, uracil mustard and 5-fluoro uracil, de -
pressed hematopoiesis in the calf. It was of significance to note that 
the depression of hemopoiesis resulted in the evolution of a pattern of 
signs paralle ling those r eported fo r the mouse, rat, dog and monkey in 
r esponse t o these same compounds, rather than the pattern of signs 
characteristically produced in the calf due to the administration of 
TCESOM, DCVC, and bracken fern or exposure to ionizing radia tion . The 
essential difference in the two patterns of signs is t he occurrence of 
an early and profound thrombocytopenia ultima tely resulting in the 
severe hemorrhagic syndrome characteristic of calves poisoned with DCVC . 
The fact that the calf res ponds to ionizing radiation in a manner 
similar t o other mammalian species and that l abora tory anima ls respond i n 
a different manner than the calf to DCVC suggests that the DCVC r esponse 
picture in the calf is atypica l. 
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In contrast to the other three compounds tested in the calf, the 
antimetabolite, amethopterin, did not e licit any of the typical signs of 
depression of hematopoiesis evidenced in l aboratory animals even though 
levels were established that indicated the compound was profoundly toxic 
to the calf . 
As say ranges for the compounds tested were not established. The 
experiment al results did suggest levels that might be suitable for the 
assay of the two alkylating agents, mechlorethamine·HCl and uracil 
mus tard . With these two compounds, dose - degree of response-time re-
l ationships were sugges ted for the signs, thrombocytopenia, leukopenia 
and death. The results obtained for 5- FU gave no indications of degrees 
or orders of responses suitable for quantitation. The manifestations of 
the hemorrhagic signs associated with an early and profound thrombo-
cytopenia appear not to be available as additional indicators of effect 
versus dosage for these cancer chemotherapeutic compounds . 
The fact that the data obtained i ndicated that the calf was more 
sensitive than other laboratory anima ls to three of the four compounds 
evaluated, by factors of at least 2 to 5, suggests that it may be a very 
sensitive species for evaluation of certain types of marrow poisons. The 
ability of even the unrefined calf assay to differentiate the marrow 
poisoning toxicities of the structura l analogs, uracil mustard and 
mechlorethamine ·HCl, establishes a difference unreported in the literature . 
An increased ability to evaluate differences in marrow poisoning activ-
ities of cancer chemotherapeutic agents as related to their structures 
would assist in the attainment of the goal of cancer chemotherapy . 
43 
Utilization of this approach could lead to the e limination or 
reduction of toxic effects of anti - cancer agents if these toxic 
activities are independent of the anti - tumor activities. 
If the ca lf could be established as even a better system for assay-
ing the marrow poisoning capabilities, especial ly potentia l cancer 
chemotherapeutic agents, its disadvantages of size and management 
problems would be of little consequence . 
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SUMMARY 
1. The experimental findings indicate that the young calf is very 
sensitive to the hematopoietic tissue depressing properties of the 
cancer chemotherapeutic compounds, mechlorethamine ·HCl, uraci l mus t ard 
and 5- fluoro uracil. 
2 . The experimental results show that the calf responds to the effects 
of these three cancer chemotherapeut ic agents in a manner similar t o 
mice, rats, monkeys and dogs . 
3. The marked hemorrhagic lesions which are typical of the response of 
the calf to the marrow poisons, TCESOM and DCVC, are no t exhibited in 
response to the anti-canc er compounds . 
4 . The hematopoietic tissues of the young calf are not sensitive t o 
amethopterin at the levels tested. 
5 . Assay ranges for mechlorethamine ·HCl and uracil mus tard in calves 
were not estab lished although assay ranges were suggested by one or more 
of t he exhibited responses of leukopenia, thrombocytopenia or death. 
6 . The inconsistent responses observed with 5- fluoro uracil, gave no 
indication of the existence of a quantitative assay range in the calf 
for this compound. 
7. The only quantitative criterium, evidenced in response to the effec ts 
of the administration of amethopterin to calves, was death, observed only 
at the highest dosage l evels . 
8 . The observations that the calf is capable of responding in a dose-
degree of response-time relationship to the alkylating agents, uracil 
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mustard and mechlorethamine ·HCl , are highly suggestive of the calf 
being a mor e sensitive assay anima l than the dog and monkey . These 
r esponses indicate t ha t the calf is more sensitive than the s e two 
species by a fa ctor of 2 to 5 . 
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APPENDIX I. CONTROL CALF 
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Figure 2 . Calf 947 . Leukocyte counts 
12,000 
11,000 
10,000 
9,000 
8,000 
CALF:#: 947 
NORMAL- CONTROL 
WBC (TOTAL} 
-- - LYMPHOCYTE 
----- SEGS. 
PER Cu. MM 
1~00 A 
1' " I \ / /\ /A.. 
s,ooo \ I 'J \ I/ \., '--.... 
\ I 
5,ooo \ I \I 
~ ~ 
4,000 I\ '~ --- ---
' ' 
~000 \ 
2,000 
1,000 
\ ;-----
, " / ' \.. '-- --_j 
, __ 
I \ "" 
{\ 
I \ 
I \ 
,'\ 
, 
I I ' \ ' , \1 \I 
10 20 30 40 50 60 70 80 90 100 110 120 
DAYS 
Figure 2 . (Continued) 
12,000 
11/)00 
10,000 
9,000 
8,000 
f\ 7.,000 
/
/"<..,........ I \ ...-- __..,,.,,, 
\ .....---6,000 
5,000 
-./ \ I 
J 
4,000 
3,000 
2,000 
120 130 140 150 160 l70 180 
DAYS 
I 
CALF+t947 
NORMAL 
(CON'T) 
--- VJBC(TOTAU 
--- LYMPHOCYTE 
· ----- SEGS. 
PER Cu. MM 
HS 
13gm. 
12gm. 
II gm. 
IOgm. lOO°lo 
9gm. 90°/o 
Sgm. 80°/o 
7Qm. 70°/o 
6gm. 60°/o 
5Qrn. 50°/o 
4gm. 40°/o 
3om. 30°/o 
CALF# 947 
NORM AL-CONTROL 
HEMATOCRIT 
--- HEMOGLOBIN 
1 I I I I I I I I I I I I 
10 20 30 40 50 60 70 80 90 100 110 120 
DAYS 
Figur e 3 . Ca l f 947 . Hema toc rit and he moglobin 
°' 0 
Figure 3. (Continued) 
HB 
12gm 
llgm. 
I Ogm. I 00''/o 
9gm. 90°/o 
8 800/0 . gm. I < 
7gm. 70°/o 
Ggm. 60°/o 
5gm. 50°/o 
4Qm. 40°/o 
3gm. 30°/o 
2gm. 20°/o 
120 130 140 l ~O 160 170 
DAYS 
CALF tt 947 
NORi\1AL 
(CON1T) 
--- HEMATOCRJT 0/o 
- -- HEUOGLOBINgm.0/o 
290 
270 
2 50 
230 
210 
190 
LBS. 
170 
15 0 
130 
110 
90 
CALF #- 947 
NORMAL 
WEIGHT 
7QL-~'--~1-..~..l.._~...L_~-'-~--'-~-'-~--'-~---'~~'--~J..---' 
10 20 30 40 50 60 70 80 00 100 110 120 
DAYS 
Figure 4. Calf 947. We i g ht and clinical data 
390 
370 
350 
33 
310 
LBS. 
290 
270 
250 
230 
210 
CALFi+ 947 
NORMAL (CON1T) 
WEIGHT 
7J~__.___.~-'---'~_.____._~_._____,_~_,__._~_,__---J 
120 130 140 150 160 170 180 190 200 210 220 230 ·240 
DAYS 
Figure 4. (Continued) 
65 
APPENDIX II. CALVES TREATED WITH MECHLORETHAMINE ·HCl 
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Figure 11. Calf 977 . Thrombocyte coun t s 
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Figure 12. Calf 97 7 . Leukocyte counts 
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Figure 13. Calf 977. Hematocrit and hemog l obin 
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Figure 14. Ca l f 977 . Weight and clinical data 
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Figure 15 . Calf 953. Thrombocyte counts 
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Figure 16 . Ca l f 953 . Leukocy t e coun t s 
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Figure 17 . Calf 953 . Hernatocrit and hemog lobin 
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Fi gure 18. Calf 953. Weight and c linica l data 
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Figure '19. Calf 958 . Th rombocy t e c oun t s 
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Figure 20 . Calf 958. Leukocyte counts 
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Fi gur e 21. Calf 958 . Hema tocr i t and hemoglobin 
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APPENDIX III . CALF TREATED WITH DIMETHYLACETAMIDE 
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Calf 945 . Thrombocyte counts 
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Figure 24. Calf 945. Leukocyte c ounts 
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Figur e 25 . Ca lf 942. Hema t oc ri t a nd hemogl obin 
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Figure 25. (C ontinued) 
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Figure 26 . Calf 945 . Weight and c l inical data 
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APPENDIX IV. CALVES TREATED WITH URACIL MUSTARD 
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Figure 2 7. Calf 946 . Thrombocyte counts 
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Figure 28. Calf 946. Leukocy te counts 
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Figure 29 . Ca l f 946. Hema tocrit and hemoglob i n 
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Figure 3 0 . Ca l f 946 . We i gh t and clin ica l da t a 
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Figure 31. Cal f 979. Th r ombocyte c ounts 
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Figure 32 . Ca lf 979 . Leukocyte counts 
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Figure 33 . Calf 979. Hematocrit and hemoglobin 
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Figure 34 . · Calf 979. Weight and clinica l data 
0 
600,000 
500,000 
400,000 
300,000 
200,000 
100,000 
102 
CALF~952 
URACIL MUSTARD 
44µ.g./Kg 
W/DlMETHYLACETAM IDE 
THROMBOCYTES /Cu.MM 
-5 0 I 0 20 30 40 50 60 66 
DAYS 
Figure 35. Calf 952 . Thrombocyte coun ts 
12,000 
11,000 
10,000 
9,000 
8,000 
7,000 
6,000 
5,000 
4,000 
2,000 
1,000 
\ 
'-.... 
103 
CALF tt:952 
URACIL MUSTARD 
44µ.g./Kg 
W/DIMETHYLACETAMIDE 
WBC (TOTAL) 
- - - - LYMPHOCYTE 
------ SEGS 
PER Cu. MM 
' 
-5 0 I 0 20 30 40 50 6 0 66 
DAYS 
Figure 36 . Calf 952 . Leukocyte counts 
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Figur e 37 . Calf 952. Hematocrit and h emog l obin 
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Figure 38 . Calf 952 . Weight and clinical data 
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Figur e ·3 9 . Calf 956 . Thr ornboc y te counts 
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Figure 40 . Calf 956. Leukocyte counts 
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Figure 41. Calf 956 . Hematocrit and hemoglobin 
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Figure 42 . Calf 956. We ight and c lin ica l data 
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Figure 43 . Calf 955. Thrombocyte counts 
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Figure 44 . Calf 955. Leukocyte counts 
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Figure 45. Calf 955. Hematocrit and hemog lobin 
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Figure 46 . Calf 955. Heigh t and c l inical data 
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APPENDIX V. CALVES TREATED WITH 5-FLUORO URACIL 
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Figure 47. Ca lf 750 . Thrombocy t e counts 
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Figure 48 . Calf 7 50 . Leukocyte coun t s 
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Figure 49. Calf 750 . Weight and clinical data 
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Figure 50 •. Calf 950. Thrombocyte counts 
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Figure 51. Calf 950 . Leukocyte coun t s 
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Figure 52. Ca lf 950 . Weigh t and clinical data 
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Figur e 53. Calf 948 . Thrombocyte counts 
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Figure 54~ Ca l f 948 . Leukocyte counts 
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Figure SS . Ca l f 948 . Hematocr i t and hemoglobin 
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Figure 56. Calf 948. Weight and clinical data 
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F igure 57. Ca l f 951 . Thrombocyt e c ounts 
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Figur e 58 . Ca l f 951 . Leukocy t e count s 
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Figure 59. Calf 951. Hematocrit and hemog l obin 
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Figure 60 . Calf 951. Weight and clinical data 
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Figure 61 . Calf 788 . Thr ombocyte count s 
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Figure 62. Calf 788 . Leukocyte counts 
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Figure 63. Calf 788 . Hematocrit and hemog l obin 
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F igure 64 . Calf 788 . Weight a nd c l inic al data 
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Figure 65. Ca lf 980 . Thrombocyte count s 
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F igure 66 . Ca l f 980 . Leukocy t e coun t s 
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Figure 67 . Calf 980 . Hematocrit and hemog l obin 
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Figure 68 . Ca lf 980. Weight and clinical data 
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APPENDIX VI . CALVES TREATED WITH AMETHOPTERIN 
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Figure 69 . Calf 842. Thrombocyte counts 
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Figu r e 70 . Ca l f 842 . Leukocyte coun ts 
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Figure 71 . Calf 842 . Weigh t and clinical data 
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Figure 72 ~ Calf 943 . Thrombocyte counts 
12.000 
J 1.000 
10.000 
9,000 
8,000 
7,000 
6,000 
5,000 
4 ,000 
3,000 
2.000 
1,000 
142 
CALFt:+-943 
METHOTREXATE 0.143 mg./Kg 
WSC (TOTAL) 
----- LYMPHOCYTE 
----- SEGS 
PER Cu. MM 
~ 1\ 
\ /' \ 
I ' !\ "'- ,,/ \ 
\ I 
v 
-5 0 5 10 15 20 2530 354045 50 5560 65 70 7578 
DAYS 
Figure 73. Calf 943 . Leukocyte counts 
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F igure 74 . Ca lf 943 . We i gh t and clinical da t a 
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Figure 75. Calf 978 . Thrombocyte counts 
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Figure 76 . Calf 978 . Leukocyte coun t s 
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Figure 77. Calf 978 . Hematocrit and hemoglobin 
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Figure 78 . Calf 978. Weight and clinical data 
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Figure 79. Calf 784. Thrombocyte counts 
I 
6,000 
5,000 
4,000 
3,000 
.... 
2,000 
1,000 . " 
149 
,_ 
/. 
' \ 
\ 
\ 
CALF # 784 
METHOTREXATE 1.109mg1KQ 
WBC (TOTAL) 
---- - LYMPHOCYTE 
----- SEGS 
PER Cu.MM 
-5 0 57 
DAYS 
Figure 80. Calf 784. Leukocyte counts 
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Figure 81. Ca l f 784. Hema t oc r i t and hemog l obin 
150 
130 
110 
LBS 
90 
c:::J DIARRHEA 
7
95 0 57 
15 1 
DAYS 
CALF+t784 
METHOTREXATE l.109mg./Kg. 
WEIGHT 
Figure 82. Calf 784 . Weight and clinical data 
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Figure 83 . Calf 792 . Thrombocyte coun t s 
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Figure 84. Calf 792 . Leukocyte counts. 
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Fi g ure 85 . Ca l f 7 92 . Hema toc r i t and h emog l obin 
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Figure 86. Calf 792 . Weight and c lin ical data 
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